Amedisys (AMED) Competitors

DaVita (NYSE:DVA) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Which has more volatility and risk, DVA or AMED?

DaVita has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.

Which has stronger valuation & earnings, DVA or AMED?

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$12.82B	0.76	$936.34M	$10.17	13.37
Amedisys	$2.40B	1.38	$43.23M	$2.57	39.30

Is DVA or AMED more profitable?

DaVita has a net margin of 6.35% compared to Amedisys' net margin of 3.56%. DaVita's return on equity of 369.39% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.35%	369.39%	4.62%
Amedisys	3.56%	12.91%	7.29%

Do institutionals and insiders hold more shares of DVA or AMED?

90.1% of DaVita shares are held by institutional investors. Comparatively, 94.4% of Amedisys shares are held by institutional investors. 1.5% of DaVita shares are held by company insiders. Comparatively, 2.1% of Amedisys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts rate DVA or AMED?

DaVita currently has a consensus price target of $164.00, suggesting a potential upside of 20.58%. Amedisys has a consensus price target of $100.50, suggesting a potential downside of 0.50%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amedisys	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer DVA or AMED?

In the previous week, DaVita had 17 more articles in the media than Amedisys. MarketBeat recorded 20 mentions for DaVita and 3 mentions for Amedisys. Amedisys' average media sentiment score of 0.76 beat DaVita's score of 0.75 indicating that Amedisys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	12 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amedisys	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DaVita and Amedisys tied by winning 8 of the 16 factors compared between the two stocks.